Psoriatic arthritis

Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Retrieved on: 
화요일, 4월 16, 2024
Psoriatic arthritis, Launch, HCP, Rheumatology, Patient, Need for Speed, Benchmarking, MOA, RealTime, IL-17A, Growth, Overalls, Ankylosing spondylitis, Pharmaceutical industry

Approximately five months post-approval, over one-third of US rheumatologists (n=104) report prescribing the IV formulation for their patients with PsA.

Key Points: 
  • Approximately five months post-approval, over one-third of US rheumatologists (n=104) report prescribing the IV formulation for their patients with PsA.
  • Furthermore, the vast majority feel the new formulation of Novartis’ IL-17-inhibitor brings some degree of advance over existing PsA treatments.
  • Receptivity to the IV formulation has also resulted in a greater affinity for the Cosentyx brand overall, specifically in comparison to long-standing IL-17 rival, Eli Lilly’s Taltz.
  • Launch tracking of Bimzelx will commence following approval and will continue for the first eighteen months of availability through the Launch Dynamix™ service.

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Retrieved on: 
화요일, 4월 16, 2024
Volunteering, FDA, Psoriatic arthritis, Safety, Food, Cytokine, Johnson & Johnson, Teva, TEVA, Inflammation, Partnership, Perfusion, Biotechnology, Senior, Patient, Psoriasis, Marketing, PASI, Teva Pharmaceuticals, Generic drug

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.

Key Points: 
  • Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.
  • Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure.
  • SELARSDI is the second biosimilar approved under the strategic partnership: in February 2024, the FDA approved SIMLANDI®, the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA.
  • The FDA approval of SELARSDI, referred to as AVT04 during development, was based on a totality of evidence, including analytical and clinical data.

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
수요일, 4월 10, 2024
Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Partnership, Research, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Marketing, Moonlake, Prevalence, Pharmaceutical industry

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Retrieved on: 
화요일, 4월 16, 2024
Biotechnology, Pharmaceutical, Oncology, Health, FDA, Health Technology, Genetics, Clinical Trials, Volunteering, Psoriatic arthritis, Safety, Food, Cytokine, Johnson & Johnson, Teva, TEVA, Inflammation, Partnership, Perfusion, Senior, Patient, Psoriasis, Multimedia, Marketing, PASI, Teva Pharmaceuticals, Generic drug

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.

Key Points: 
  • Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.
  • Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure.
  • SELARSDI is the second biosimilar approved under the strategic partnership: in February 2024, the FDA approved SIMLANDI®, the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA.
  • The FDA approval of SELARSDI, referred to as AVT04 during development, was based on a totality of evidence, including analytical and clinical data.

Popular ArthritisPower® Patient Registry Expands Conditions and Becomes PatientSpot™

Retrieved on: 
월요일, 4월 15, 2024
Technology, FDA, Managed Care, Health, General Health, Health Technology, Medical Devices, Research, Apps, Applications, Artificial Intelligence, Science, Conditional sentence, Education, University, Patient, Psoriatic arthritis, Food, Spondyloarthropathy, Partnership, Human, Habit, Intelligence, Entrepreneurship, Arthritis, MPH, Rheumatoid arthritis, Medicine, UAB, Movement, RMD, Nursing

Patients can now join the registry and its community with any chronic condition they wish to share, establishing it as a truly disease-agnostic platform.

Key Points: 
  • Patients can now join the registry and its community with any chronic condition they wish to share, establishing it as a truly disease-agnostic platform.
  • Erik Stone, MA, Associate Director, Learning Experience Design at GHLF, explained, “Many of the patients we assist navigate multiple chronic conditions alongside arthritis.
  • It emerged as an innovative nationwide research registry, focusing on patients with rheumatic and musculoskeletal conditions (RMD), including rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis.
  • “We treasure the insights and experiences shared by patients dealing with arthritis and related conditions.

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Retrieved on: 
수요일, 4월 10, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Other Technology, Research, Software, General Health, Health Technology, Science, Data Management, Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Marketing, Partnership, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Multimedia, Moonlake, Prevalence, Pharmaceutical industry

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240410438883/en/
    Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision-making across its clinical operations, medical, marketing, and market access teams.
  • Tino Anthamatten, VP, Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.
  • The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035.

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Retrieved on: 
목요일, 4월 11, 2024
Pain, Itch, Psoriatic arthritis, Rheumatology, Conference, Research, Science, Mental health, Antimicrobial spectrum, Diagnosis, Dermatology, Knowledge, Nursing

This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."

Key Points: 
  • This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."
  • We are honored to have April Armstrong, Chair of the Scientific Executive Committee (SEC), as the President of the 7th IFPA Conference.
  • By attending workshops, seminars, and keynote presentations, participants can enhance their knowledge and skills in various aspects of psoriatic disease.
  • Engage with leading experts, participate in insightful discussions, and contribute to shaping the future of psoriatic disease research and advocacy.

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Retrieved on: 
목요일, 4월 11, 2024
Pain, Itch, Psoriatic arthritis, Rheumatology, Conference, Research, Science, Mental health, Antimicrobial spectrum, Diagnosis, Dermatology, Knowledge, Nursing

This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."

Key Points: 
  • This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."
  • We are honored to have April Armstrong, Chair of the Scientific Executive Committee (SEC), as the President of the 7th IFPA Conference.
  • By attending workshops, seminars, and keynote presentations, participants can enhance their knowledge and skills in various aspects of psoriatic disease.
  • Engage with leading experts, participate in insightful discussions, and contribute to shaping the future of psoriatic disease research and advocacy.

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on: 
수요일, 4월 3, 2024
Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points: 
  • Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
  • In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
  • “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
  • Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on: 
수요일, 4월 3, 2024
Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points: 
  • Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
  • In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
  • “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
  • Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).